Headquartered in Zürich, Switzerland, Baxter’s EMEA organization employs more than 14,700 people in over 35 countries. Sales in Europe, the Middle East and Africa (EMEA) amounted to almost $4 billion in 2010.
In addition to over 25 sales and marketing sites in the region, Baxter has 22 production sites in 13 EMEA countries that manufacture products distributed to Baxter markets around the world. Plants in Austria, Belgium, Ireland, Spain, Switzerland, the UK and others produce some 600 million units of Medication Delivery and Renal products each year, along with several million tons of Bioscience products for biotherapeutics, hemophilia, biosurgery and vaccine therapy.
Led by EMEA President Peter Nicklin, Baxter EMEA is organized into eight geographic clusters, corresponding to the diverse market environments present in the region. Baxter’s two business groups – Bioscience and Medical Products (Medication Delivery and Renal) – are responsible for providing products and therapies for tens of thousands of patients across the region.
Baxter is the leading provider of products used in hemophilia therapy across the region. In Russia, where Baxter is the Hemophilia market leader, the Russian government recently awarded Baxter the largest tender in the company’s history for the provision of plasma-derived FVIII product.
Vaccine therapy is another driver of Baxter growth in EMEA. In 2010, Baxter’s innovative influenza vaccine, PREFLUCEL, was launched in Austria and the Czech Republic before being made available to other markets across the region in 2011.
Baxter also manufactures a variety of plasma-based biotherapeutic therapies for the treatment of life-threatening conditions such as immune-system disorders. In this area, Baxter partners with organizations such as the Jeffrey Modell Foundation (JMF) to help raise awareness amongst patients and caregivers about immune deficiency illnesses and their treatments. In partnership with the Foundation, Baxter has now opened almost a dozen JMF centres for Primary Immunodeficiency research in countries across EMEA, including Belgium, Ireland, Italy, the Netherlands and Switzerland.
Europe is the second largest market, after the United States, for Baxter’s Medication Delivery products. A leading supplier of intravenous (IV) solutions in non-PVC flexible containers in EMEA, the company produced almost 400 million IV bags in its EMEA manufacturing facilities in 2010 alone. In addition, Baxter provides electronic and portable IV infusion pumps, administration sets and access devices, which control the flow of IV fluids to patients.
The EMEA market leader for parenteral nutrition, Baxter has a complete portfolio of IV administered nutrition products. These include nutrition solutions and innovative multi-chamber container systems such as Olimel for adult critical care patients and Numeta, the first three-chamber bag especially developed for at term and pre-term babies up to two years of age. With Olimel, launched across Europe in 2010, and the rest of its nutrition offering, Baxter is able to meet the needs of patients in both hospitals and at home. In fact, Baxter has over thirty years of experience in home healthcare, with more than a third of its sales involving products to be used by patients in the home.
In Anesthesia, Baxter is the only company to offer all three modern inhalation agents used in general anesthesia: Suprane® (desflurane), Sevoflurane and Isoflurane. In EMEA, the use of Suprane® (desflurane) continues to show double-digit growth, while Sevoflurane, the most widely used inhalation anesthetic, is now registered and marketed in over a dozen European countries as well as in several Middle Eastern markets.
Baxter’s Renal business provides products and services for end-stage renal disease and acute kidney injury (reversible kidney failure). In addition to being a leader in renal home therapies for peritoneal dialysis (PD), the business also distributes products for hemodialysis and continuous renal replacement therapy (CRRT). Major manufacturing sites are based close to customers in the region to facilitate delivery to home PD patients. Baxter has established home delivery services in several countries, including Belgium, the Netherlands, the UK and Spain.
Europe is home to much of the research and development for Baxter’s global product portfolio. With three major sites in Belgium (Alliance Park) and Austria (Vienna and Orth), Baxter EMEA attracts and partners with Europe’s top scientists, researchers, engineers and academics on the development of innovative new treatments and therapies for some of the most life-threatening diseases and illnesses. Key Baxter products and therapies resulting from our European R & D centres include twin bag packaging for continuous ambulatory peritoneal dialysis (CAPD), triple chamber bags for parenteral nutrition, biocompatible solutions for peritoneal dialysis and a resorbable bone substitute, just to name a few. In addition, Baxter partners with European research universities and sponsors a number of scientific awards and fellowships aimed at encouraging and supporting European-based medical research.
Fostering an inclusive and diverse work environment is one of the key principles of Baxter EMEA’s approach to talent management and employee engagement. Under the guidance of EMEA’s inclusion and diversity committee, a particular focus is increasing the number of women in leadership positions in the region. As a result of positive employee feedback on Baxter’s workplace environment, a number of EMEA sites - including Austria, Denmark, France, Ireland, the Netherlands, Poland, Portugal, Spain and Switzerland - have been recognised as one of their country’s Best Workplaces by local “Great Place to Work” organizations.
In addition to the Great Place to Work recognition in several countries, Baxter EMEA sites have also been recognized for outstanding achievement in environmental, corporate responsibility (CSR) and scientific areas. A number of Baxter’s sites have achieved ISO EHS certification, others have been recognized for their commitment to CSR, and still others, have been recognised by the scientific community, such as Baxter Italy for its innovative Smartphone application for hemophilia patients.
In 2010, charitable giving from Baxter and The Baxter International Foundation, the philanthropic arm of the corporation, totaled more than $80 million, with almost half a million dollars given in charitable grants in EMEA. In addition, the region donated more than $9 million in product to not-for-profit organizations and $8.3 million in business unit contributions to charitable organizations addressing community needs.
Baxter employees are also actively engaged in the community. Through December 2010, Baxter employees around the world logged over 163,000 volunteer hours as part of Baxter’s Global Service Project. In EMEA, employees recorded 14,500 volunteer hours in the community through involvement in a range of initiatives.